Prophylactic potential of honey and Nigella sativa L. against hospital and community-based SARS-CoV-2 spread: a structured summary of a study protocol for a randomised controlled trial

Sohaib Ashraf1,2*, Shoaib Ashraf2,3*, Rutaba Akmal4*, Moneeb Ashraf5*, Larab Kalsoon6*, Aadil Maqsood7*, Muhammad Ahmad Imran8*, Iqra Farooq9*, Sidra Ashraf10*, Uzma Nasim Siddiqui11*, Muhammad Ghufan12*, Muhammad Kiwan Akram13*, Nighat Majeed14*, Sundas Rafique15*, Zaigham Habib16*, Muhammad Sarmad Shahab17*, Adeel Akmal18*, Zeeshan Shaukat1*, Zain ul Abidin1*, Ayesha Khaza1*
Shahroze Arshad8, Muhammad Abdul Rehman Virk11, Mehak Gul11, Abeer bin Awa11, Muhammad Hassan11, Noman Khalid11, Qurrat Ul Ain Iqbal11, Tausif Ahmad11, Muaz Akram11, Ameer Muhammad11, Musa Khalil11, Aneeq Aslam11, Muhammad Umer19, Syed Sami Hussain Sherazi20*, Zartasha Safdar20*, Sohail Ahmad21*

Muhammad Bilal22, Muhammad Nauman Zahid23, Abdulrahman E. Koshak24, Abubakar Hilal1, Ahmad Azam Malik25, Usman Iqbal26, Atif Amin Baig27, Yaser Masuod Alahmadi28, Ayesha Humayun29, Amber Malik1, Ali Ahmad30, Muhammad Ashraf21, Qazi Abdul Saboor1, Mateen Izhar8* and DOCTORS LOUNGE consortium

* Correspondence: sohaib-ashraf@outlook.com; sohaib@skzmdc.edu.pk; shoaib.ashraf@mail.mcgill.ca; rutabaakmal@gmail.com; moneeb.ashraf@hotmail.com; larab.kalsoom@outlook.com; aadilmaqsood@utoledo.edu; ahmad.imran@skzmdc.edu.pk; iqrafarooq93@gmail.com; sidraashraf@uvas.edu.pk; uzmamamoon@gmail.com; mateen@cantab.net
† Sohaib Ashraf, Shoaib Ashraf, Rutaba Akmal, Moneeb Ashraf, Larab Kalsoon, Aadil Maqsood, Muhammad Ahmad Imran, Iqra Farooq, Sidra Ashraf and Muhammad Ghufan are joint first authors.
† Uzma Nasim Siddiqui, Muhammad Kiwan Akram, Nighat Majeed, Sundas Rafique, Zaigham Habib and Muhammad Sarmad Shahab are joint second authors.
1Department of Cardiology, Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan
2Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
3Department of Internal Medicine, Sahara Medical College, Narowal, Pakistan
4Department of Pharmacology, Mayo Hospital, Kingedward Medical University, Lahore, Pakistan
5Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan
6Department of Pulmonary & Critical Care Medicine, University of Toledo Medical Center, Toledo, Ohio, USA
7Department of Microbiology, Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan
8Department of Paediatric Surgery, Children Hospital, Lahore, Pakistan
9Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, Pakistan
10Department of Medicine, Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan

Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Abstract

Objectives: Considering the therapeutic potential of honey and Nigella sativa (HNS) in coronavirus disease 2019 (COVID-19) patients, the objective of the study is defined to evaluate the prophylactic role of HNS.

Trial design: The study is a randomized, placebo-controlled, adaptive clinical trial with parallel group design, superiority framework with an allocation ratio of 1:1 among experimental (HNS) and placebo group. An interim analysis will be done when half of the patients have been recruited to evaluate the need to adapt sample size, efficacy, and futility of the trial.

Participants: All asymptomatic patients with hospital or community based COVID-19 exposure will be screened if they have had 4 days exposure to a confirmed case. Non-pregnant adults with significant exposure level will be enrolled in the study

- High-risk exposure (<6 feet distance for >10min without face protection)
- Moderate exposure (<6 feet distance for >10min with face protection)

Subjects with acute or chronic infection, COVID-19 vaccinated, and allergy to HNS will be excluded from the study. Recruitment will be done at Shaikh Zayed Post-Graduate Medical Institute, Ali Clinic and Doctors Lounge in Lahore (Pakistan).

Intervention and comparator: In this clinical study, patients will receive either raw natural honey (0.5 g) and encapsulated organic Nigella sativa seeds (40 mg) per kg body weight per day or empty capsule with and 30 ml of 5% dextrose water as a placebo for 14 days. Both the natural products will be certified for standardization by Government College University (Botany department). Furthermore, each patient will be given standard care therapy according to version 3.0 of the COVID-19 clinical management guidelines by the Ministry of National Health Services of Pakistan.

Main outcomes: Primary outcome will be Incidence of COVID-19 cases within 14 days of randomisation. Secondary endpoints include incidence of COVID-19-related symptoms, hospitalizations, and deaths along with the severity of COVID-19-related symptoms till 14th day of randomization.

Randomisation: Participants will be randomized into experimental and control groups (1:1 allocation ratio) via the lottery method. There will be stratification based on high risk and moderate risk exposure.

Blinding (masking): Quadruple blinding will be ensured for the participants, care providers and outcome accessors. Data analysts will also be blinded to avoid conflict of interest. Site principal investigator will be responsible for ensuring masking.

Numbers to be randomised (sample size): 1000 participants will be enrolled in the study with 1:1 allocation.

Trial Status: The final protocol version 1.4 was approved by institutional review board of Shaikh Zayed Post-Graduate Medical Complex on February 15, 2021. The trial recruitment was started on March 05, 2021, with a trial completion date of February 15, 2022.

Trial registration: Clinical trial was registered on February 23, 2021, www.clinicaltrials.gov with registration ID NCT04767087.

Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). With the intention of expediting dissemination of this trial, the conventional formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines.

Keywords: Honey, Nigella Sativa, Prophetic Medicine, Pakistan, COVID-19, Randomised controlled trial, Protocol
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s13063-021-05510-3.

Additional file 1: Full protocol.

Acknowledgements
The authors would like to acknowledge Prof. Dr. Zaheer Ahmad, PhD (Department of botany, Government College University, Lahore, Pakistan). We pay gratitude to late Prof. Zia Ullah (Internal Medicine, Shaikh Zayed Post-Graduate Medical Complex) who died while serving humanity and combating COVID-19. We are particularly grateful for the help of our local collaborators including DOCTORS LOUNGE Consortium.

DOCTORS LOUNGE Consortium
Arz Muhammad1, Kanwal Hayat1, Ghazala Amjad1, Misbah Kousar1, Umair Hafeez2, Tayyab Mughal1, Tayyaba Muzafar1, Sibgha Zulfiqar1, Saadia Shahzad Alam1, Muhammad Imran Anwar1, Amber Malik1, Talha Mahmud1, Ali Anhadi1, Khawar Nawaz1, Muhammad Ismail Khalid Yousaf1.

Affiliations: 1. Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan. 2. Kingedward Medical University, Lahore, Pakistan. 3. Sunny Downstate/Kings Country Medical Center, New York, USA. 4. University of Louisville, Kentucky, USA.

Authors’ contributions
SA, SHA, MA, AM, SR, MAI, UK, LNS, NW, IF, RK, and MG contributed equally to this paper and share first authorship. SA, ShA, MA, AM, and AA are joint corresponding authors. KAUNS, NM, IF, and RA contributed equally and share joint second authorship. SA, ShA, MA, AM, SR, MAI, LR, and MG added to the conception, designing and manuscript drafting. SA, ShA and MoA proposed the hypothesis and study design. MA, MuA, SIA, MKA, NW, MG, ZH, MKA, SR, ZH, ZS, contributed biochemical, dosimetry, pharmacological as well as pharmaceutical inputs. SA, MoA, SR, AZ, RK, and SR drafted the first version of the manuscript. Doctors Lounge Consortium IF, RA, MSS, SRI, AH, AM, ZS, ZA, AK, KH, GM, MlK, SA, Mh, QuAl, AmA, ABA, Mu, ABH, SSBS, ZS, AnT, KM, TM and MU contributed significantly to designing the final methodology. MKA, SoA, and AH provided statistical inputs. AAM, UsI, Msu, SZ, SS, SSA, MIA, AnM, TM, Ah, YMA, QAS, AA, MoA and MI have contributed to intellectual inputs in the study protocol and methodology along with final manuscript write up. All authors are responsible for their contributions, providing critical edits and final authorization of the article. The corresponding authors attest trial validity and authenticity. All authors read and approved the final manuscript.

Funding
Funding by Smile Welfare Organization (SWO) - a non-profitable organization. The funder played no role in the design of the study, in the collection, analysis, and interpretation of data, and in writing the manuscript.

Availability of data and materials
All required data will be posted along with the trial results and final trial dataset requests can be made to Dr. Sohaib Ashraf which could be available from the author on reasonable appeal subject to data protection regulations. (Twitter: SohaibAshrafMD, email address: sohaib@skzmdc.edu.pk, Mobile Number: +92 334474523)

Declarations
Ethics approval and consent to participate
The trial was approved by institutional ethical review board of Shaikh Zayed Post-Graduate Medical Complex (IRB ID # SZMC/IRB/Internal/273/2021) on February 15, 2021. Authors certify that the study has received ethical approval from the appropriate ethical committee as stated above. Before enrolment, all participants will be fully informed of the study and asked to sign the consent form to be eligible for randomization and participation.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Cardiology, Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan. 2Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA. 3Department of Pathobiology, Ripah International, Lahore, Pakistan. 4Department of Internal Medicine, Sahara Medical College, Narowal, Pakistan. 5Department of Pharmacology, Mayo Hospital, Kingedward Medical University, Lahore, Pakistan. 6Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan. 7Department of Pulmonary & Critical Care Medicine, University of Toledo Medical Center, Toledo, Ohio, USA. 8Department of Microbiology, Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan. 9Department of Paediatric Surgery, Children Hospital, Lahore, Pakistan. 10Institute of Biochemistry and Biotechnology, University of Veterinary and Animal Sciences, Lahore, Pakistan. 11Department of Medicine, Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan. 12ESACHS (Empresa de Servicio Externo de la Asociación Chilena de Seguridad), Punta Arenas, Chile. 13Department of Animal Nutrition, University of Veterinary and Animal Sciences, Lahore, Pakistan. 14Department of Internal Medicine, Services Institute of Medical Sciences, Lahore, Pakistan. 15Department of Radiotherapy, Mayo Hospital, King Edward Medical University, Lahore, Pakistan. 16Department of Orthopedics, Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan. 17Department of Internal Medicine, Allied Hospital, Faisalabad Medical University, Faisalabad, Pakistan. 18Department of Surgery, University of Veterinary and Animal Sciences, Lahore, Pakistan. 19Department of Gastroenterology, Shaikh Zayed Post-Graduate Medical Institute, Lahore, Pakistan. 20Department of Pharmacology and Toxicology, University of Veterinary and Animal Sciences, Lahore, Pakistan. 21Department of Department of Poultry Production, University of Veterinary and Animal Sciences, Lahore, Pakistan. 22Department of Animal Science, McGill University, Sainte-Anne-de-Bellevue, Quebec, Canada. 23Department of Biology, college of Science, University of Bahrain, Sakhir, Kingdom of Bahrain. 24Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia. 25Department of Family and Community Medicine, Rabigh Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. 26Global Health and Development Department, College of Public Health, Taipei Medical University, Taipei, Taiwan. 27Unit of Biochemistry, Faculty of Medicine, University Sultan Zainal Abidin, Terengganu, Malaysia. 28Clinical and Hospital Pharmacy Department, College of Pharmacy, Taibah University Medina, Medina, Kingdom of Saudi Arabia. 29Department of Community Medicine and Public Health, Shaikh Zayed Post-Graduate Medical Complex, Lahore, Pakistan. 30Department of Microbiology, Infectiology and Immunology, Centre Hospitalier Universitaire (CHU) Sainte Justin/University of Montreal, Montreal, Canada.

Received: 29 July 2021 Accepted: 4 August 2021
Published online: 15 September 2021

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions